ストックスクリーナーアプリを入手
102.12
0.87%
0.88
プレマーケット:
102.15
0.03
+0.03%
前日終値:
$101.24
開ける：
$102
24時間の取引高:
568.61K
Relative Volume:
1.01
時価総額：
$8.07B
収益：
-
当期純損益:
$-425.38M
株価収益率:
-17.46
EPS:
-5.8504
ネットキャッシュフロー:
$-275.21M
1週間 パフォーマンス:
-0.18%
1か月 パフォーマンス:
-6.18%
6か月 パフォーマンス:
-3.55%
1年 パフォーマンス:
+39.45%
1日の値動き範囲:
$101.24
$103.94
1週間の範囲:
$98.62
$103.94
52週間の値動き範囲:
$70.25
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
Compare NUVL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
102.12 | 8.00B | 0 | -425.38M | -275.21M | -5.8504 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-30 | 開始されました | Wells Fargo | Overweight |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-12 | 開始されました | Canaccord Genuity | Buy |
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-10-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-09-03 | 開始されました | Raymond James | Outperform |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-03-14 | アップグレード | UBS | Neutral → Buy |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-08-29 | 開始されました | Barclays | Overweight |
| 2024-04-17 | 開始されました | Jefferies | Buy |
| 2024-04-01 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 再開されました | Guggenheim | Buy |
| 2024-02-23 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-27 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-24 | 開始されました | Guggenheim | Buy |
| 2023-01-18 | 開始されました | Wedbush | Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
すべてを表示
Nuvalent Inc (NUVL) 最新ニュース
The Technical Signals Behind (NUVL) That Institutions Follow - Stock Traders Daily
Nuvalent, Inc. (NUVL) Stock Analysis: Evaluating a Potential 41.52% Upside in Biotech Innovation - DirectorsTalk Interviews
How Investors May Respond To Nuvalent (NUVL) NDA Filing And Early Zidesamtinib Response Data - Yahoo Finance
Bernstein initiates coverage of Nuvalent (NUVL) with outperform recommendation - MSN
Nuvalent’s SWOT analysis: biotech stock gains momentum on clinical data By Investing.com - Investing.com South Africa
Nuvalent’s SWOT analysis: biotech stock gains momentum on clinical data - Investing.com
NUVL Initiated Coverage by Bernstein -- Rating Set to Outperform - GuruFocus
Bernstein Initiates Nuvalent at Outperform - Moomoo
Nuvalent (NUVL) Receives Outperform Rating with $189 Target from Bernstein - GuruFocus
Bernstein initiates Nuvalent stock coverage with outperform rating By Investing.com - Investing.com Nigeria
Bernstein initiates Nuvalent stock coverage with outperform rating - Investing.com
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting - PR Newswire
Nuvalent ASCO 2026 Data Puts Neladalkib And Zidesamtinib In Focus - Sahm
Nuvalent Highlights Corporate and Pipeline Achievements and Repo - GuruFocus
CCORF Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $126 - Moomoo
Assessing Nuvalent (NUVL) Valuation After Recent Share Price Volatility And DCF Upside Signals - simplywall.st
Stifel Maintains Nuvalent (NUVL) Buy Recommendation - MSN
Precision Trading with Nuvalent Inc. (NUVL) Risk Zones - Stock Traders Daily
J.P. Morgan Maintains Nuvalent(NUVL.US) With Buy Rating, Cuts Target Price to $147 - Moomoo
TradingKey - TradingKey
H.C. Wainwright Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $155 - Moomoo
Nuvalent, Inc. (NUVL) Stock Analysis: 35% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
LifeSci Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $142 - Moomoo
Truist Financial Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Guggenheim Maintains Nuvalent(NUVL.US) With Buy Rating, Cuts Target Price to $151 - Moomoo
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $140 to $152 - Moomoo
Nuvalent: Buy Rating Reiterated on Strong Oncology Pipeline, Commercial Readiness, and Unchanged $142 Price Target - TipRanks
Nuvalent, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nuvalent Inc-A (NASDAQ:NUVL) Stock Edges Higher After Q1 2026 Earnings Miss as Investors Focus on Pipeline Milestones - ChartMill
Nuvalent (NUVL) widens Q1 loss as R&D spend rises and cash tops $1.3B - Stock Titan
Nuvalent (Nasdaq: NUVL) posts Q1 loss, advances dual lung cancer NDAs - Stock Titan
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results – Company AnnouncementFT.com - Financial Times
Nuvalent CEO James Porter sells $3.05m in NUVL shares, exercises options - Investing.com Canada
Nuvalent(NUVL.US) Officer Sells US$3.05 Million in Common Stock - Moomoo
Nuvalent (NUVL) CEO exercises options and sells 30,000 common shares - Stock Titan
Nuvalent earnings in focus as drug launch looms By Investing.com - Investing.com South Africa
Nuvalent earnings in focus as drug launch looms - Investing.com UK
FMR LLC reports 9.25M Nuvalent shares (12.6%) (NASDAQ: NUVL) - Stock Titan
Nuvalent CFO Balcom sells $1.13m in company stock By Investing.com - Investing.com South Africa
Nuvalent CFO Balcom sells $1.13m in company stock - Investing.com
Nuvalent (NUVL) CFO sells 11,430 shares, exercises options under plan - Stock Titan
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium - Quantisnow
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 43.75% Potential Upside with Promising Oncology Innovations - DirectorsTalk Interviews
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock - MarketBeat
Nuvalent Insider Sold Shares Worth $547,524, According to a Recent SEC Filing - marketscreener.com
Nuvalent Insider Sold Shares Worth $545,691, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CLO sells shares, exercises options in 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CDO nets 5,500-share sale after option exercise - Stock Titan
Canaccord Genuity Sticks to Their Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Nuvalent Inc (NUVL) 財務データ
収益
当期純利益
現金流量
EPS
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):